Waverley Pharma Inc.
WAVE.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 15.90% | 18.11% | -759.70% | 19.92% | 46.14% |
| Total Depreciation and Amortization | -1.34% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.00% | -60.15% | 515.63% | -455.56% | -91.51% |
| Change in Net Operating Assets | 153.07% | -1,853.85% | 112.46% | 70.44% | -35.42% |
| Cash from Operations | 73.07% | -72.42% | -104.05% | 56.13% | -66.81% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | 100.00% | -152,800.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -100.00% | 31,500.00% |
| Total Debt Issued | -57.97% | 240.15% | -15.73% | 146.46% | -65.64% |
| Total Debt Repaid | -7.69% | 4.88% | 0.00% | 4.65% | 13.13% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -60.19% | 269.77% | -17.31% | 213.25% | -72.56% |
| Foreign Exchange rate Adjustments | 133.33% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 204.29% | 71.80% | -2,323.08% | 104.04% | -2,579.17% |